These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 34619517)
1. Facing Counterfeit Medications in Sexual Medicine. A Systematic Scoping Review on Social Strategies and Technological Solutions. Sansone A; Cuzin B; Jannini EA Sex Med; 2021 Dec; 9(6):100437. PubMed ID: 34619517 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States. Nunes AP; Seeger JD; Stewart A; Gupta A; McGraw T J Sex Med; 2021 Sep; 18(9):1511-1523. PubMed ID: 34389264 [TBL] [Abstract][Full Text] [Related]
3. The dangers of sexual enhancement supplements and counterfeit drugs to "treat" erectile dysfunction. Chiang J; Yafi FA; Dorsey PJ; Hellstrom WJ Transl Androl Urol; 2017 Feb; 6(1):12-19. PubMed ID: 28217446 [TBL] [Abstract][Full Text] [Related]
4. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. Shindel AW J Sex Med; 2009 Sep; 6(9):2352-64; quiz 2365-6. PubMed ID: 19735356 [TBL] [Abstract][Full Text] [Related]
5. The silent development of counterfeit medications in developing countries - A systematic review of detection technologies. Bolla AS; Patel AR; Priefer R Int J Pharm; 2020 Sep; 587():119702. PubMed ID: 32736015 [TBL] [Abstract][Full Text] [Related]
6. Fake drugs, real concerns: Counterfeit HIV medications and community trust. Ware KB; Campbell RD; Turner M Res Social Adm Pharm; 2023 Apr; 19(4):686-691. PubMed ID: 36460561 [TBL] [Abstract][Full Text] [Related]
7. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction. Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103 [TBL] [Abstract][Full Text] [Related]
8. [Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?]. Baydaroglu E; Eschwège P; Hubert J; El Osta R Prog Urol; 2019; 29(6):326-331. PubMed ID: 31151915 [TBL] [Abstract][Full Text] [Related]
9. Update on counterfeit antibiotics worldwide; public health risks. Delepierre A; Gayot A; Carpentier A Med Mal Infect; 2012 Jun; 42(6):247-55. PubMed ID: 22621827 [TBL] [Abstract][Full Text] [Related]
10. Profiling characteristics of men who use phosphodiesterase type 5 inhibitors based on obtaining patterns: data from the nationwide Japanese population. Kimura M; Shimura S; Kobayashi H; Tai T; Chikano Y; Baba S; Kano M; Nagao K J Sex Med; 2012 Jun; 9(6):1649-58. PubMed ID: 22513057 [TBL] [Abstract][Full Text] [Related]
11. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. Yafi FA; Sharlip ID; Becher EF Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561 [TBL] [Abstract][Full Text] [Related]
12. A survey on illegal and counterfeit medicines for the treatment of erectile dysfunctions in Italy. Gaudiano MC; Manna L; Rodomonte AL; Bartolomei M; Bertocchi P; Gallinella B; Antoniella E; Muleri N; Civitelli G; Alimonti S; Romanini L; Rufini L; Valvo L J Sex Med; 2012 Aug; 9(8):2130-7. PubMed ID: 22612848 [TBL] [Abstract][Full Text] [Related]
13. Criminal Action Against Drug Counterfeiters: Assessment of the FDA Office of Criminal Investigation Database 2016 Through 2021. White CM Ann Pharmacother; 2022 Dec; 56(12):1333-1338. PubMed ID: 35502467 [TBL] [Abstract][Full Text] [Related]
14. Sexual Rehabilitation After Nerve-Sparing Radical Prostatectomy: Free-of-Charge Phosphodiesterase Type 5 Inhibitor Administration Improves Compliance to Treatment. Siena G; Mari A; Canale A; Mondaini N; Chindemi A; Greco I; Saleh O; Serni S; Nicita G; Minervini A; Carini M J Sex Med; 2018 Feb; 15(2):120-123. PubMed ID: 29425663 [TBL] [Abstract][Full Text] [Related]
15. Counterfeit drugs and medical devices in developing countries. Glass BD Res Rep Trop Med; 2014; 5():11-22. PubMed ID: 32669888 [TBL] [Abstract][Full Text] [Related]
16. The health and economic effects of counterfeit drugs. Blackstone EA; Fuhr JP; Pociask S Am Health Drug Benefits; 2014 Jun; 7(4):216-24. PubMed ID: 25126373 [TBL] [Abstract][Full Text] [Related]
17. Assessing the problem of counterfeit medications in the United Kingdom. Jackson G; Patel S; Khan S Int J Clin Pract; 2012 Mar; 66(3):241-50. PubMed ID: 22070229 [TBL] [Abstract][Full Text] [Related]
19. Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example. Sugita M; Miyakawa M Environ Health Prev Med; 2010 Jul; 15(4):244-51. PubMed ID: 21432552 [TBL] [Abstract][Full Text] [Related]
20. Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy. Nsimba SE East Afr J Public Health; 2008 Dec; 5(3):205-10. PubMed ID: 19374325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]